Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153970 | 0.83 | ALDH1A1 (0.50) | ALDH1A1CES1CES2SMN1; SMN2MAPK1 | |
| SCHEMBL9169283 | 0.78 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL11425982 | 0.78 | TSHR (0.51) | ALDH1A1CES1CES2SMN1; SMN2MEN1 | |
| SCHEMBL3049742 | 0.78 | TP53 (0.49) | ALDH1A1CES1CES2MAPTMEN1 | |
| SCHEMBL7584692 | 0.76 | MAPT (0.42) | ALDH1A1CES1CES2SMN1; SMN2MAPT | |
| SCHEMBL733060 | 0.76 | MEN1 (0.47) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL7244076 | 0.75 | MAPT (0.34) | CES1CES2MAPTMEN1KMT2A | |
| SCHEMBL11422463 | 0.73 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2MAPK1MAPTMEN1 | |
| SCHEMBL9319913 | 0.73 | KMT2A (0.51) | ALDH1A1MAPK1MAPTKMT2ALMNA | |
| SCHEMBL6152726 | 0.73 | POLB (0.44) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812051-B2 | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2006020722-A2 | POLYMER CONJUGATES OF BETA-LAPACHONE AND BETA-LAPACHONE ANALOGS FOR TUMOR TARGETING | ARQULE, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | ARQULE, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | NQO1, KEAP1, DLD | ALDH1A1 929/4885CES1 837/4885CES2 2315/4885 |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | QPCT, KEAP1, SLC46A1 | ALDH1A1 1063/4885CES1 2502/4885CES2 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.